thress, that is impossible because if it were true then RONIN would not be after PPHM.
One does not see the value of potential in the pipelines as long as it isn't realised. It is 650 Mil$ I think and we get part back via tax advantage build-up.
Avid is clearly no squandered money. It is an established business with 5 consecutive years growing revenue. One needs to make it look like it failed by using the forecasts for the next year rather then the balance sheets. And the new targeting platform also looks like an unique selling proposition for Avid.
Last article on the NASDAQ list mentioned an almost 400% growth comparison.
Exosome based liquid biopsies for all solid cancers are completely new and not for from emerging as a commercial product after tests with ovarian, peer-reviewed paper with super results of ovarian test, improvement of the test and currently finalising the proof-of-concept test kit. Then partnering.
And a 200+ patent portfolio including the above liquid biopsy based on PS and the PS-targeting IP for Bavituximab and BetaBodies.
So CAR-T, Immuno-Oncology, Chemo and Radio combination are all open. Bavituximab is ABSOLUTELY 100% safe with no meaning side effects of its own and the drug NEVER failed to perform as scheduled (at the most it failed clinical trials due to anomalies in the control arms that dramatically over performed or were tempered with by a 3rd party CRO).
So the VALUE is there, it just hasn't been leveraged yet and if there is ONE THING that we could reproach the company (BoD/management) then it is the timing...the fact that this hasn't took place yet.
Then, maybe then, one can think about partial (PS) squandering.